FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

FDA's accelerated drug approvals often lack confirmatory evidence

FDA's accelerated drug approvals often lack confirmatory evidence

FDA Approves Rexulti for Agitation Associated With Dementia Due to

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug

How the FDA approved an antipsychotic that failed to show a

FDA fast-tracking approval of new drugs — fewer trials, less info

vtgn20220331_10k.htm

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA approves world's first vaccine for 'emerging global health